CONNECT WITH US:
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
Jun 17, 2020 18:00 JST
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020.
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
Jun 01, 2020 13:00 JST
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies.
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
Apr 24, 2020 10:00 JST
SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million).
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
Mar 18, 2020 11:00 JST
Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak.
Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats
Nov 15, 2019 02:00 JST
Global BioLife Inc, the U.S.subsidiary of SGX-listed Singapore eDevelopment Ltd (SeD), will present research on its 3F Antimicrobial Fragrance as a new method to prevent and treat Tuberculosis at the 2020 ASM Biothreats conference, taking place from 28 to 30 January 2020 in Arlington, Virginia.
Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis
Oct 29, 2019 09:00 JST
SGX-listed Singapore eDevelopment Limited ("SeD", SGX:40V) wishes to announce that its biomedical subsidiary incorporated in Nevada, Global BioLife Inc. ("Global BioLife") will be presenting its research on its Functional Fragrance Formula ("3F") against tuberculosis at the 2020 American Society for Microbiology ("ASM") Biothreats Conference.
Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
Jul 24, 2019 15:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce the results of clinical trials conducted on Laetose(TM), developed by its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife").
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
Jun 12, 2019 14:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) wishes to announce that its U.S. biomedical subsidiary Global BioLife Inc. has independently tested its new 3F Mosquito Formula which performs well against mosquitoes for six (6) to eight (8) hours.
Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
Jan 28, 2019 12:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has developed 3F Antimicrobial Fragrance, which shows efficacy against tuberculosis.
Singapore eDevelopment's Global BioLife to present Parkinson's Research at Neuroscience 2018
Nov 07, 2018 19:00 JST
Singapore eDevelopment (SGX: 40V) ("SeD") subsidiary, Global BioLife Inc. is pleased to announce that research of their promising drug platform, Linebacker, will be presented at Neuroscience 2018, the Annual Meeting for the International Society for Neuroscience (SfN) in San Diego, California.
Singapore eDevelopment Limited Announces Corporate and Business Update
Jun 18, 2018 19:00 JST
The Board of Directors of Singapore eDevelopment Limited wishes to provide shareholders an update on the Group's operations.
Singapore eDevelopment's Global BioLife develops Low Glycemic Modified Sugar
May 31, 2018 18:00 JST
Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife, Inc. ("Global BioLife"), has developed a low glycemic index, naturally modified sugar - Laetose - which has the potential to affect the world's sugar market.
Singapore eDevelopment's Global BioLife confirms LB2 efficacy against Ebola
Mar 01, 2018 14:00 JST
Singapore eDevelopment (SGX: 40V; SeD) is pleased to announce biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for the study of new anti-viral drug LB2, part of its new universal therapeutic drug platform, Linebacker.
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
Nov 01, 2017 18:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) announced today that its U.S. biomedical subsidiary, Global BioLife Inc. has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric.
Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar
Oct 24, 2017 18:00 JST
SGX-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife Inc. has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose -- which has the potential to affect the world's sugar market.
Singapore eDevelopment's Global BioLife and Chemia Corp. to develop 3F suite of Functional Fragrances
Aug 15, 2017 19:00 JST
Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne diseases, diminish stress and anxiety, and act in anti-viral medical applications.
First-Year Performance of Global Systematic Multi-Strategy Fund
Jun 15, 2017 10:15 JST
The Board of Directors of Singapore eDevelopment Ltd ("SeD") wishes to announce that its Global Systematic Multi-Strategy Fund ("GSMS Fund") managed by Hengfai Asset Management Pte Ltd ("HFAM"), a wholly owned subsidiary of SeD's investment-arm SeD Capital Pte Ltd, achieved a gross and net return of 15% and 10%, respectively, in its first year of operation.
Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform
May 22, 2017 11:00 JST
Singapore eDevelopment Limited ("SeD") subsidiary Global BioLife Inc. has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer.
Fujitsu Revamps Corporate Philosophy 'FUJITSU Way' to Achieve Our Purpose
Jul 01, 2020 14:22 JST
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID
Jul 01, 2020 14:02 JST
Toyota Launches New Acceleration Suppression System
Jul 01, 2020 13:48 JST
Tohoku University and NEC Collaborate to Accelerate the Development of Composite Materials for Aircraft
Jul 01, 2020 13:41 JST
MHIEC Receives Order to Refurbish Core Equipment of the Kushiro Wide-Area Federation WtE Plant in Kushiro, Hokkaido
Jun 30, 2020 16:58 JST
Toyota Launches Stamping-Type Plating Machine that Significantly Reduces Environmental Impact and Transforms Plating Process
Jun 30, 2020 13:51 JST
NTT Anode Energy and Mitsubishi Corporation Agree to Study Cooperation in the Energy Sector Business
Jun 30, 2020 12:40 JST
Fujitsu and NetApp Enhance Strategic Partnership for Data Management Infrastructure
Jun 30, 2020 10:17 JST
Honda Releases Production, Sales and Export Results in May 2020
Jun 29, 2020 17:35 JST
Mazda Production and Sales Results for May 2020
Jun 29, 2020 16:05 JST
Toyota Releases Sales, Production, and Export Results for May 2020
Jun 29, 2020 14:22 JST
SPARX Group Establishes Space Frontier Fund
Jun 29, 2020 14:08 JST
MHI Machine Tool to Launch Ultra-thin Precision Position Detectors
Jun 29, 2020 13:37 JST
NEC Platforms provides highly functional bioplastic, "NeCycle," helping to solve environmental issues such as marine plastic waste
Jun 29, 2020 12:34 JST
Fujitsu Global Survey Demonstrates How Digital Transformation Provides Value to Society
Jun 29, 2020 10:06 JST
Hitachi and Microsoft Form a Strategic Alliance to Advance Next-generation Digital Solutions for Manufacturing and Logistics across Southeast Asia, North America and Japan
Jun 26, 2020 14:00 JST
Showa Denko Group Recycles 4.43 Million Aluminum Cans in FY2019
Jun 26, 2020 14:00 JST
MHI Group to Participate in Establishment of The Mærsk Mc-Kinney Møller Center for Zero Carbon Shipping
Jun 25, 2020 16:25 JST
NEC: Alliance for Joint Research and Development and Global Rollout of ICT Products Utilizing Innovative Optical and Wireless Technologies
Jun 25, 2020 15:06 JST
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea
Jun 25, 2020 11:47 JST
More Latest Release >>